SARA RYGOL: Open Payments
NPI 1184657603 · COUNCIL BLUFFS, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,087 in 105 payments from 20 companies in 2025. Trend: 2023 $1,670 · 2024 $2,493 · 2025 $4,087
Consulting: $2,000Food & beverage: $1,960Education: $127
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 37 | $2,713 |
| AstraZeneca Pharmaceuticals LP | 13 | $295 |
| Novo Nordisk Inc | 13 | $204 |
| Astellas Pharma US Inc | 4 | $170 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $106 |
| Otsuka America Pharmaceutical, Inc. | 5 | $94 |
| Lilly USA, LLC | 5 | $91 |
| PFIZER INC. | 5 | $80 |
| Gilead Sciences, Inc. | 2 | $49 |
| Vanda Pharmaceuticals Inc. | 2 | $45 |
Products named: QULIPTA, VRAYLAR, UBRELVY, Ozempic, REXULTI, CAPLYTA, LINZESS, FARXIGA.
Industry payments across IA — which companies pay providers there.
